EUVIMEDEUVIMED entdecken
Crossref

Integrated In Silico and In Vitro Evaluation of Trillium govanianum Metabolites against Key Protein Targets in Non‐Small Cell Lung Cancer

Lubna Tariq, Basharat Ahmad Bhat, Zahid Ahmed Mangral, Rubiya Dar, Shahid Ul Islam, Venkatramanan Varadharajan, Kaisar Ahmad Bhat, Tanvir Ul Hassan Dar

ChemistrySelect · 2026-11 · 11 (42)

DOI: 10.1002/slct.75125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 10.11.2026. Verfasst von Lubna Tariq und 7 weiteren Autor:innen. Die Arbeit nennt 99 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trillium govanianum was investigated for its potential anti‐lung cancer activity against Non‐small cell lung cancer (NSCLC) using an integrated metabolomic, computational, and experimental approach. Ultra‐performance liquid chromatography coupled with electrospray ionization‐mass spectrometry (UPLC‐ESI‐MS) profiling of petroleum ether (PE), hexane (Hex), ethyl acetate (EtOAc), and methanol (MeOH) extracts putatively annotated bioactive metabolites, including Diosgenin, Pennogenin E, Govanoside A, Trillarin, Polyphyllin VII, and Sarsasapogenin. Network pharmacology analysis integrated NSCLC associated targets from multiple databases with predicted metabolite targets, revealing 374 overlapping targets associated with NSCLC. Protein‐protein interaction analysis identified EGFR, SRC, VEGFA , and STAT3 as major hub proteins involved in cancer progression. Molecular docking studies demonstrated strong binding affinities of the metabolites toward these targets, with Govanoside A showing the highest affinity for EGFR (−11.3 kcal/mol) through multiple hydrogen bond interactions. In vitro cytotoxicity testing on A‐549 lung cancer cells showed that the MeOH extract exhibited the strongest anticancer activity, reducing cell viability to approximately 35% at 500 µg/mL. Furthermore, all metabolites displayed favorable, ADMET characteristics and satisfied Lipinski's Rule of Five. Overall, these findings suggest that T. govanianum possesses promising multi‐target therapeutic potential against NSCLC, potentially through the modulation of the EGFR, SRC, VEGFA , and STAT3 signaling pathways.

Zitieren

APA

Tariq, L., Bhat, B. A., Mangral, Z. A., Dar, R., Islam, S. U., Varadharajan, V., Bhat, K. A., & Dar, T. U. H. (2026). Integrated In Silico and In Vitro Evaluation of Trillium govanianum Metabolites against Key Protein Targets in Non‐Small Cell Lung Cancer. ChemistrySelect, 11(42). https://doi.org/10.1002/slct.75125

Vancouver

Tariq L, Bhat BA, Mangral ZA, Dar R, Islam SU, Varadharajan V, et al. Integrated In Silico and In Vitro Evaluation of Trillium govanianum Metabolites against Key Protein Targets in Non‐Small Cell Lung Cancer. ChemistrySelect. 2026;11(42). doi:10.1002/slct.75125

BibTeX
@article{Tariq2026,
  author = {Tariq, Lubna and Bhat, Basharat Ahmad and Mangral, Zahid Ahmed and Dar, Rubiya and Islam, Shahid Ul and Varadharajan, Venkatramanan and Bhat, Kaisar Ahmad and Dar, Tanvir Ul Hassan},
  title = {Integrated In Silico and In Vitro Evaluation of Trillium govanianum Metabolites against Key Protein Targets in Non‐Small Cell Lung Cancer},
  journal = {ChemistrySelect},
  year = {2026},
  volume = {11},
  number = {42},
  doi = {10.1002/slct.75125}
}
Kostenlos starten →